Abstracts tagged "cytokines and systemic lupus erythematosus (SLE)"

Abstract Number: 1081 • 2018 ACR/ARHP Annual Meeting
Associations between Daily Alcohol Intake and SLE-Related Cytokines and Chemokines U.S. Female Nurses without SLE
Cianna Leatherwood¹, Xinyi Liu¹, Susan Malspeis², Andrea Roberts³, Jeffrey A. Sparks¹, Elizabeth Karlson¹, Candace H. Feldman¹, Judith A. James⁴, Laura Kubzansky⁵ and Karen Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Harvard T.H. Chan School of Public Health, Boston, MA, ⁴OMRF & OUHSC, Oklahoma City, OK, ⁵Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Low or no alcohol intake (0-5 gm/day or <0.5 drinks/day) has been associated with increased SLE risk among women. Several cytokines and chemokines are…
Abstract Number: 1693 • 2018 ACR/ARHP Annual Meeting
Innate, Adaptive, and TNF-Superfamily Immune Pathways Inform a Lupus Disease Activity Immune Index That Characterizes Disease Activity in SLE
Melissa E. Munroe^1,2, Joel M. Guthridge¹, Rufei Lu^1,3, Joseph M. Kheir¹, Bolanle Adebayo¹, Susan R. Macwana¹, Hua Chen¹, Virginia C. Roberts¹, Mohan Purushothaman², Sanjiv Sharma², Teresa Aberle¹, Stan Kamp¹, Cristina Arriens¹, Eliza Chakravarty¹, Katherine Thanou¹, Joan T. Merrill¹ and Judith A. James^4,5, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Progentec Diagnostics, Inc., Oklahoma City, OK, ³Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease marked by immune dysregulation. A comprehensive but cost-effective tool to track relevant mediators of altered…
Abstract Number: 1743 • 2017 ACR/ARHP Annual Meeting
Serine Arginine/Rich Splicing Factor 1 (SRSF1) Increases IL-2 Production in T Cells By Increasing the Expression of NFAT and c-Fos
Takayuki Katsuyama¹, Michael W. Mosho¹, George C. Tsokos¹ and Vaishali R. Moulton², ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) produce insufficient amounts of the vital cytokine IL-2, and the molecular mechanisms leading to this…
Abstract Number: 1776 • 2016 ACR/ARHP Annual Meeting
Analysis of Progressive Brain and Corpus Callosum Atrophy and Association with Th1 and Th2 Cytokines in Systemic Lupus Erythematosus
Mariana Postal¹, Aline Tamires Lapa¹, Karina O. Peliçari¹, Nailu A. Sinicato², Fernando A. Peres¹, Wesley Geraldo Ferreira³, Lilian TL Costallat³, Fernando Cendes³ and Simone Appenzeller⁴, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Pediatrics, State University of Campinas, Campinas, Brazil, ³State University of Campinas, Campinas, Brazil, ⁴Division of Rheumatology, Faculty of Medical Science, State University of Campinas, São Paulo, Brazil
Background/Purpose: The pathophysiology of brain damage SLE is complex. The aim of this study was to determine brain atrophy progression and the association with Th1…
Abstract Number: 2818 • 2016 ACR/ARHP Annual Meeting
High Sensitivity Multiplex ELISA Reveals Cytokine Expression Heterogeneity in Active SLE
John A. Reynolds¹, Sahena Haque², Eoghan M. McCarthy³, Jamie C Sergeant⁴, Elaine Lee⁵, Eileen Holling Lee⁵, Steven Kilfeather⁵, Benjamin Parker⁶ and Ian N. Bruce⁷, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²Rheumatology department, University Hospitals of South Manchester NHS Foundation Trust, Manchester, United Kingdom, ³NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom, ⁴Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK, Manchester, United Kingdom, ⁵Aeirtec Limited, UK, North Shields, United Kingdom, ⁶Centre for Musculoskeletal Research, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁷Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Patients with SLE have a broad clinical and immunological phenotype in which multiple immune pathways may be sequentially or simultaneously activated. No reliable biomarkers…
Abstract Number: 2835 • 2016 ACR/ARHP Annual Meeting
Longitudinal Analysis of Th1 and Th2 Cytokines in Systemic Lupus Erythematosus
Mariana Postal¹, Karina O. Peliçari¹, Nailu A. Sinicato², Aline Tamires Lapa¹, Fernando A. Peres¹, André Moreno Morcillo³, Lilian TL Costallat³ and Simone Appenzeller⁴, ¹Medicine, State University of Campinas, Campinas, Brazil, ²Pediatrics, State University of Campinas, Campinas, Brazil, ³State University of Campinas, Campinas, Brazil, ⁴Division of Rheumatology, Faculty of Medical Science, State University of Campinas, São Paulo, Brazil
Background/Purpose: While autoantibodies production and immune complex deposition are cornered as hallmark features of systemic lupus erythematosus (SLE), there is growing evidence to propose the…
Abstract Number: 2935 • 2016 ACR/ARHP Annual Meeting
Activation Status of Mucosal-Associated Invariant T Cells Sensitively Reflects Disease Activity of Systemic Lupus Erythematosus
Asako Chiba¹, Goh Murayama², Mie Kitagaichi³, Naoto Tamura⁴, Ken Yamaji², Yoshinari Takasaki⁴ and Sachiko Miyake¹, ¹Immunology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes that express a semi-invariant TCRα chain: Vα7.2-Jα33 in humans and Vα19-Jα33 in mice. MAIT cells are…
Abstract Number: 1829 • 2015 ACR/ARHP Annual Meeting
Heart Rate Variability Is Associated with SLE Flare and with TNF- and IFN-Mediated Signaling
Aikaterini Thanou¹, Stavros Stavrakis², John Dyer², Stan Kamp³, Melissa E. Munroe¹, David Albert⁴, Judith A. James⁵ and Joan T. Merrill³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Heart Rhythm Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴AliveCor, Inc., San Francisco, CA, ⁵Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Decreased heart rate variability (HRV), associated with adverse outcomes in cardiovascular diseases, is frequently seen in patients with SLE. The LF/HF ratio, a HRV…
Abstract Number: 1855 • 2015 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Exosomes Contain Distinct RNA Transcripts That Differentiate Disease Activity and Modulate Cellular Function
Samantha Slight-Webb¹, Krista M. Bean¹, Nicolas Dominguez¹, Mikhail G. Dozmorov², Judith A. James³ and Joel M. Guthridge¹, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clincial Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease involving multiple organ systems and periods of waxing and waning disease activity. The lack of…
Abstract Number: 2066 • 2015 ACR/ARHP Annual Meeting
Elevated Innate, Adaptive, and TNF-Superfamily Soluble Inflammatory Mediators Mark Impending Disease Flare, While Regulatory Mediators Distinguish Lack of Impending Disease Flare in African-American SLE Patients with Active Disease
Melissa E. Munroe¹, Evan G. Vista², Joan T. Merrill³, Joel M. Guthridge¹, Virginia C. Roberts¹ and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ³Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a multifaceted disease characterized by immune dysregulation and varied disease activity. Identifying mechanistic mediators of altered disease activity would help prevent damage…
Abstract Number: 3156 • 2015 ACR/ARHP Annual Meeting
IL17 Promotes Development of Autoreactive Early Stage B Cells in Distinct Regions of the Spleen Follicle
Jennie Hamilton¹, Qi Wu², PingAr Yang³, Jun Li⁴, Yanna Ding¹, Bao Luo⁵, John Mountz⁶ and Hui-Chen Hsu², ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Dept of Med/Rheumatology Div, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The early stage transitional B cell has been shown to be the key peripheral B-cell tolerance control point defect in SLE patients. Anti-RNP Abs can…
Abstract Number: 2734 • 2014 ACR/ARHP Annual Meeting
B55β Regulates T Cell Survival through the Modulation of AKT during Cytokine Deprivation
José C. Crispin¹, Sokratis A. Apostolidis², Noe Rodriguez Rodriguez¹, Tran Nguyen² and George C. Tsokos³, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Rheumatology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose . The abundance of cytokines controls the length of immune responses through poorly defined mechanisms. B55β is a molecule that triggers apoptosis in activated…
Abstract Number: 1944 • 2014 ACR/ARHP Annual Meeting
Targeting CD22 with Epratuzumab Impacts Cytokine Production By B Cells
Vanessa Fleischer^1,2, Julia Sieber^1,2, Sarah J. Fleischer^3,4, Anthony Shock⁵, Guido Heine⁶, Capucine Daridon^1,2 and Thomas Dörner^1,2, ¹CC12, Dept. Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ²German Rheumatism Research Centre Berlin, Berlin, Germany, ³Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology/German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Department of Medicine/Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁵UCB Pharma, Slough, United Kingdom, ⁶Department of Dermatology, Venerology and Allergology, Charité University Medicine Berlin, Berlin, Germany
Background/Purpose CD22 is a negative co-receptor of the B-cell receptor (BCR) and, when targeted by epratuzumab, partially inhibits BCR signaling, for example by reducing Syk…
Abstract Number: 1942 • 2014 ACR/ARHP Annual Meeting
Regulation of the Responses of Human B Cell Subsets to Innate Immune Signals By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22
Natalia V. Giltiay¹, Geraldine L. Shu², Anthony Shock³ and Edward A. Clark⁴, ¹Department of Immunology, Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Immunology, University of Washington, Seattle, WA, ³UCB Pharma, Slough, United Kingdom, ⁴Department of Immunology and Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose The B cell-associated receptor, CD22, functions to regulate adhesion and signaling through both the B cell receptor (BCR) and Toll-like receptors (TLRs) expressed in…
Abstract Number: 1602 • 2013 ACR/ARHP Annual Meeting
Autoantibodies, Cytokines and Chemokines In Serum and Cerebrospinal Fluid Of SLE Patients With Cognitive Dysfunction
Hilda Fragoso-Loyo¹, Alí Duarte-García², Sandra Juárez-Arellano³, Alba Cicero-Casarrubias⁴, Juanita Romero-Díaz⁵, Luis LLorente-Peters¹ and Jorge Sánchez-Guerrero⁶, ¹Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²Department of Medicine, Tufts Medical Center, Boston, MA, ³Department of Neurology, Instituto Nacional de Ciencias Medicas y Nutricion S.Z., Mexico city, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁵Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁶Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada
Background/Purpose: The nature and pathogenesis and cognitive dysfunction (CD) in patients with SLE is unkown.To determine the presence and levels of autoantibodies, cytokines and chemokines…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.